CNNMoney.com
Companies Economy International Corrections Pre-market Trading After-hours Trading Winners/Losers/Actives Bonds Currencies Commodities World Markets Money Magazine Real Estate Taxes Jobs Ask the Expert Money 101 Autos Mutual Funds The Help Desk Loan Center Best Places to Live Ask the Expert Ultimate Guide to Retirement Retirement Calculators Rules of Retirement Best Funds Best Places to Retire Fortune Brainstorm Tech Apple 2.0 Blog Big Tech Blog Sectors and Stocks Tech Talk Resource Guide Small Business Makeovers Questions & Answers Small Business Video 100 Best Places to Launch FSB 100 Fortune Small Business Fortune 500 Brainstorm Tech Investing Management C-Suite Rankings Main Create Portfolio Edit Portfolio Create Alerts Edit Alerts

Pfizer drug linked to higher heart failure rate

Small study shows cancer patients taking Pfizer's Sutent suffered 15% rate of heart failure, higher than in clinical trials.

Subscribe to Companies
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all CNNMoney.com RSS FEEDS (close)
By Aaron Smith, CNNMoney.com staff writer

Heart, brain health linked
CNN's Dr. Sanjay Gupta reports on new findings that emphasizes the connection between heart health and brain health.

NEW YORK (CNNMoney.com) -- A new study released at a conference on Tuesday shows that Pfizer's cancer drug Sutent may be linked to more instances of heart failure than previously thought.

Some 15% of patients suffered heart failure when taking Sutent, according to results from a small study, announced at the Genitourinary Cancers Symposium in San Francisco.

The study found that seven out of 48 patients receiving Sutent experienced heart failure. This is a higher rate than previously recognized, according to the American Society of Clinical Oncology (ASCO), co-sponsor of the symposium.

Prior results from clinical trials showed an 8% heart failure rate, according to ASCO. The new study, lead by researcher Dr. Melinda Telli of the Stanford University School of Medicine, was not a clinical trial, and tracked patients from 2004 to 2007.

Dr. Telli acknowledged that the study was "limited by the numbers," but said "it's possible that the true incidence of heart failure could be even higher." She said that doctors should conduct routine monitoring of Sutent patients to detect problems with heart function.

Barbara Ryan, analyst for Deutsche Bank North America, said that the issue "probably warrants further investigation," but it's difficult to draw any conclusions, "given the small size of the study."

Sutent is an FDA-approved treatment for cancer of the kidney and digestive system. Sales for the drug totaled $581 million in 2007, up 166% from $219 million the prior year.

Pfizer (PFE, Fortune 500) did not fund this study.

Pfizer spokeswoman Vanessa Aristide said that Pfizer has not had an opportunity to review the data. But she stressed that cardiovascular events are acknowledged on Sutent safety labels, along with recommendations for monitoring patients with cardiac risk factors.

She also said the risk-benefit profile of Sutent is "well established," and the drug has been studied in 33,000 people. To top of page

Photo Galleries
Biggest losers: Where Americans aren't moving Through most of the decade Florida was one of the fastest growing states. But the sunny clime -- and 6 others -- lost more residents than they gained in the year ended July 1. More
8 hot cars: Class of 2000 In just 10 years, the market's changed a lot when it comes to cars. Where are these models now? The Prius became a hit; the Aztek got killed. More
Obama's Main Street favorites President Obama meets often with small business owners, peppering his speeches with their stories. We checked in with 6 entrepreneurs touted by the President to find out how they handle health care. More
Sponsors
© 2009 Cable News Network. A Time Warner Company. All Rights Reserved. Terms under which this service is provided to you. Privacy Policy. Advertising Practices.
Copyright © 2009 BigCharts.com Inc. All rights reserved. Please see our Terms of Use.
MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.
Intraday data is at least 20-minutes delayed. All times are ET.
Historical, current end-of-day data, and splits data provided by Interactive Data Pricing and Reference Data.
Fundamental data provided by Morningstar, Inc..
SEC Filings data provided by Edgar Online Inc..
Earnings data provided by FactSet CallStreet, LLC.